# Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older

> **NCT00753272** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 43695 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** GSK Bio's influenza vaccine GSK2186877A
- **BIOLOGICAL:** Fluarix TM

## Key facts

- **NCT ID:** NCT00753272
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09-15
- **Primary completion:** 2010-06-18
- **Final completion:** 2011-01-05
- **Target enrollment:** 43695 (ACTUAL)
- **Last updated:** 2018-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00753272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00753272, "Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00753272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*